trending Market Intelligence /marketintelligence/en/news-insights/trending/gqfnrm_u2amdhaf-q8ltfg2 content esgSubNav
In This List

OncoSec closes first tranche of $15M investment from Alpha Holdings

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


OncoSec closes first tranche of $15M investment from Alpha Holdings

OncoSec Medical Inc. closed the first tranche of Alpha Holdings Inc.'s $15 million investment.

As part of the investment deal, the South Korean manufacturer of semiconductors purchased $8 million worth of OncoSec's common shares at $1.50 apiece.

OncoSec will use the investment to develop Tavo, or tavokinogene telseplasmid, the company's lead immunotherapy product candidate.

Meanwhile, completion of the second tranche is subject to certain closing conditions.

Pennington, N.J.-based OncoSec Medical is developing cytokine-based intratumoral immunotherapies with its proprietary technology to treat cancer.